NO20000094D0 - 6-Azaurcilderivater som IL-5 inhibitorer - Google Patents

6-Azaurcilderivater som IL-5 inhibitorer

Info

Publication number
NO20000094D0
NO20000094D0 NO20000094A NO20000094A NO20000094D0 NO 20000094 D0 NO20000094 D0 NO 20000094D0 NO 20000094 A NO20000094 A NO 20000094A NO 20000094 A NO20000094 A NO 20000094A NO 20000094 D0 NO20000094 D0 NO 20000094D0
Authority
NO
Norway
Prior art keywords
azaur
inhibitors
source derivatives
derivatives
source
Prior art date
Application number
NO20000094A
Other languages
English (en)
Other versions
NO20000094L (no
Inventor
Eddy Jean Edgard Freyne
Gustaaf Maria Boeckx
Jean Pierre Frans Van Wauwe
Gaston Stanislas Marcell Diels
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20000094D0 publication Critical patent/NO20000094D0/no
Publication of NO20000094L publication Critical patent/NO20000094L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0491Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0461Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20000094A 1997-07-10 2000-01-07 6-Azaurcilderivater som IL-5 inhibitorer NO20000094L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202117 1997-07-10
PCT/EP1998/004192 WO1999002504A1 (en) 1997-07-10 1998-07-02 6-azauracil derivatives as il-5 inhibitors

Publications (2)

Publication Number Publication Date
NO20000094D0 true NO20000094D0 (no) 2000-01-07
NO20000094L NO20000094L (no) 2000-03-08

Family

ID=8228530

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000094A NO20000094L (no) 1997-07-10 2000-01-07 6-Azaurcilderivater som IL-5 inhibitorer

Country Status (20)

Country Link
US (2) US6743792B2 (no)
EP (1) EP1003729A1 (no)
JP (1) JP2002508001A (no)
KR (1) KR20010012614A (no)
CN (1) CN1261881A (no)
AU (1) AU756637B2 (no)
BR (1) BR9811499A (no)
CA (1) CA2294533A1 (no)
EE (1) EE9900585A (no)
HR (1) HRP990333A2 (no)
HU (1) HUP0002826A3 (no)
ID (1) ID24224A (no)
IL (1) IL133915A0 (no)
NO (1) NO20000094L (no)
NZ (1) NZ501627A (no)
PL (1) PL337875A1 (no)
SK (1) SK180999A3 (no)
TR (1) TR199903249T2 (no)
WO (1) WO1999002504A1 (no)
ZA (1) ZA986095B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987265A1 (en) * 1998-09-18 2000-03-22 Janssen Pharmaceutica N.V. Interleukin-5 inhibiting 6-azauracil derivatives
AR021363A1 (es) * 1998-11-23 2002-07-17 Janssen Pharmaceutica Nv Derivados de 6-azauracilo inhibidores de la il-5
DE69936396T2 (de) 1998-12-18 2008-06-19 Janssen Pharmaceutica N.V. Il-5 hemmende 6-uracilderivate
EE200200057A (et) * 1999-08-06 2003-04-15 Janssen Pharmaceutica N.V. Kasvutegurit IL-5 pärssiv asauratsiilderivaat, selle saamine ja kasutamine ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
US8073380B2 (en) * 2005-12-30 2011-12-06 Nokia Corporation Media content delivery and recording over broadcast network

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883527A (en) 1973-10-19 1975-05-13 Pfizer Process for preparation of 2-aryl-1,3,4-triazine-3,5(2H,4H)-diones
US4631278A (en) * 1984-08-01 1986-12-23 Janssen Pharmaceutica N.V. Anti-protozoal α-aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile derivatives, pharmaceutical compositions, and method of use therefor
GB8602342D0 (en) * 1986-01-30 1986-03-05 Janssen Pharmaceutica Nv 5 6-dihydro-2-(substituted phenyl)-1 2 4-triazine-3 5(2h 4h)-diones
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
EP0476439A1 (de) * 1990-09-18 1992-03-25 Bayer Ag Substituierte 1,2,4-Triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
DE4120138A1 (de) * 1991-06-19 1992-12-24 Bayer Ag Substituierte hexahydro-1,2,4-triazindione, verfahren zu ihrer herstellung, zwischenprodukte dafuer und ihre verwendung
TW263495B (no) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
DE69615601T2 (de) * 1995-04-14 2002-07-11 Takeda Schering-Plough Animal Health K.K., Osaka Verfahren zur Herstellung von Triazinderivate

Also Published As

Publication number Publication date
ID24224A (id) 2000-07-13
BR9811499A (pt) 2000-09-19
HUP0002826A3 (en) 2003-01-28
US20030220331A1 (en) 2003-11-27
AU8441398A (en) 1999-02-08
US6743792B2 (en) 2004-06-01
CA2294533A1 (en) 1999-01-21
KR20010012614A (ko) 2001-02-15
NO20000094L (no) 2000-03-08
AU756637B2 (en) 2003-01-16
CN1261881A (zh) 2000-08-02
NZ501627A (en) 2002-02-01
SK180999A3 (en) 2000-10-09
HRP990333A2 (en) 2000-04-30
JP2002508001A (ja) 2002-03-12
HUP0002826A2 (hu) 2001-04-28
EP1003729A1 (en) 2000-05-31
ZA986095B (en) 2000-01-10
IL133915A0 (en) 2001-04-30
EE9900585A (et) 2000-08-15
WO1999002504A1 (en) 1999-01-21
US20020042416A1 (en) 2002-04-11
US6951857B2 (en) 2005-10-04
TR199903249T2 (xx) 2000-09-21
PL337875A1 (en) 2000-09-11

Similar Documents

Publication Publication Date Title
NO992725D0 (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO980467D0 (no) 4-mercaptopyrrolidin-derivater som farnesyl-transerase-inhibitorer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO985874D0 (no) Bestemte fosfinylderivater nyttige som naaladase inhibitorer
NO986090D0 (no) Fenylalaninderivater som integrininhibitorer
DK1005446T3 (da) N-aroylphenylalaninderivater
ATE235220T1 (de) Resorcinderivate
ID22781A (id) Turunan-turunan nikotinamida
DK1001934T3 (da) Indolforbindelser som COX-2-inhibitorer
DE69817186D1 (de) Diaminorhodamin-derivate
ATE236136T1 (de) Benzosulfonderivate
DK1097127T3 (da) Diacylhydrazinderivater som integrininhibitorer
ATE255098T1 (de) Substituierte chromanderivate
DK1006628T3 (da) Kilde med flere bølgelængder
ATE255099T1 (de) Substituierte chromanderivate
ATE440854T1 (de) 5-deoxy-cytidin-derivate
DK0747346T3 (da) N-acyl-2-arylcyclopropylmethylaminderivater som melatonerge midler
DE69837922D1 (de) Il-5 hemmende 6-azauracilderivate
NO20005271L (no) Optisk aktive tetrahydrobenzindol-derivater
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
DK1075471T3 (da) Idolylderivater som serotonerge midler
ATE233253T1 (de) Chromanderivate
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
DE69829682D1 (de) Cis-disubstituierte aminocycloalkyl-pyrrolidin-derivate